Preparation of Drug Delivery Systems

REVIEW Preparation of Uniform-Sized Multiple Emulsions and Micro/ Nano Particulates for Drug Delivery by Membrane Emulsication
WEI LIU,1,2 XIANG-LIANG YANG,1 W.S. WINSTON HO2,3

1 2
College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China
William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, 140 West 19th Avenue, Columbus, Ohio 43210-1180
3
Department of Materials Science and Engineering, The Ohio State University, Columbus, Ohio 43210-1178
Received 24 March 2010; revised 20 May 2010; accepted 21 May 2010 Published online 29 June 2010 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/jps.22272 ABSTRACT: Much attention has in recent years been paid to ne applications of drug delivery systems, such as multiple emulsions, micro/nano solid lipid and polymer particles (spheres or capsules). Precise control of particle size and size distribution is especially important in such ne applications. Membrane emulsication can be used to prepare uniform-sized multiple emulsions and micro/nano particulates for drug delivery. It is a promising technique because of the better control of size and size distribution, the mildness of the process, the low energy consumption, easy operation and simple equipment, and amendable for large scale production. This review describes the state of the art of membrane emulsication in the preparation of monodisperse multiple emulsions and micro/nano particulates for drug delivery in recent years. The principles, inuence of process parameters, advantages and disadvantages, and applications in preparing different types of drug delivery systems are reviewed. It can be concluded that the membrane emulsication technique in preparing emulsion/particulate products for drug delivery will further expand in the near future in conjunction with more basic investigations on this technique. 2010 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 100:7593,
2011
Keywords: membrane emulsication; drug delivery systems; multiple emulsion; micro/nano particulate; uniform size; controlled release
INTRODUCTION
Drug delivery systems (DDSs) represent one of the most rapidly advancing areas of pharmaceutical science and technology.1,2 DDSs, such as multiple emulsions, micro/nano solid lipid and polymer particles (spheres or capsules) can entrap drugs or biomolecules into their interior structures and/or absorb drugs or biomolecules onto their exterior surfaces. They are designed for targeting delivery and controlled release of drug into systemic circulation maintaining consistent efcacy and reducing dose of the drug and its related side effects. DDSs have
Correspondence to: W.S. Winston Ho (Telephone: 1-614-2929970; Fax: 1-614-292-3769; E-mail: ho@chbmeng.ohio-state.edu)
Journal of Pharmaceutical Sciences, Vol. 100, 7593 (2011) 2010 Wiley-Liss, Inc. and the American Pharmacists Association
already been applied with great success today and still have greater potential for many applications, including anti-tumor therapy, gene therapy, AIDS therapy, and radiotherapy in the delivery of proteins, antibiotics, virostatics, and vaccines as drug carriers to pass the blood-brain barrier.38 The targeting drug delivery and controlled drug release properties of DDSs are closely related to their size and size distribution. DDSs with small size can easily pass through the ne capillary blood vessels and the lymphatic endothelium.9 They have longer circulation times in the blood, higher binding capability and accumulation at the target sites, and give less inammatory and immune response from the tissues and cells of the body than those with bigger size.10,11 The narrow size distribution (monodisperse) gives better control over the dose and release behavior of the encapsulated drug, yields higher drug
75
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 100, NO. 1, JANUARY 2011
76
LIU, YANG, AND WINSTON HO
encapsulation efciency and better biocompatibility with cells and tissues of the body than that of polydisperse DDSs.9,11,12 However, the preparation of these DDSs with controlled size and size distribution is still a challenge. The conventional techniques for manufacturing multiple emulsions and micro/nano particulates include high pressure homogenization, ultrasonication method, rotor/stator systems (such as stirred vessels, colloid mills, and toothed disc dispersing machines), solvent evaporation, solvent diffusion, coacervation, spray drying and direct polymerization.1315 None of these techniques can give a good control over the size and size distribution of abovementioned emulsion and particulate products. Also, the encapsulated biomolecules such as proteins, gene and vaccines are liable to lose their bioactivities under strong mechanical processing and macro organic solvents.15,16 The membrane emulsication technique received broad attention as a novel tool for manufacturing monodisperse emulsion over the last 20 years. The technique is attractive for the better control of emulsion droplet size and size distribution, the mildness of the process, the low energy consumption, and easy to industrial-scale preparation.1719 This review describes the state of the art of the membrane emulsication technique in manufacturing uniform-sized multiple emulsions and micro/nano particulates for drug delivery in recent years. The principles, effect of process parameters, and especially applications in preparing different kinds of drug delivery systems are reviewed.
developed, such as cross-ow membrane emulsication, premix membrane emulsication, microchannel emulsication, and other membrane-based methods. Cross-Flow Membrane Emulsication The process and typical apparatus of cross-ow membrane emulsication are shown schematically in Figures 1 and 2, respectively. In cross-ow membrane emulsication, the dispersed phase is pressed through a microporous membrane (micropore diameter is dp) while the continuous phase ows along the membrane surface. Droplets grow at micropores and detach at a certain size (dd), which is determined by the balance between the forces acting on the droplet.2729 Emulsiers in the continuous phase stabilize the newly formed interface, to prevent droplet coalescence immediately after formation.26,30 Some fundamental process parameters, such as membrane parameters, process parameters and phase properties, affect the emulsion droplet size/size distribution and the dispersed phase ux during cross-ow membrane emulsication. These membrane parameters include the type of membrane material, average micropore diameter, porosity/ micropore spacing, micropore geometry, membrane thickness, and wetting property (wall contact angle). SPG membranes are the earliest and most commonly used membranes for the excellent characterization of uniform cylindrical interconnected micropores, a wild range of available mean micropore diameter (0.0530 mm), high membrane surface
PRINCIPLES OF MEMBRANE EMULSIFICATION

Membrane emulsication is a technique that involves using an applied pressure to force a dispersed phase to go through membrane pores into a continuous phase.17,20 Small droplets are formed at the pore openings on the membrane surface and dispatched by the relative shear motion between the membrane and continuous phase. The resulting droplet size is controlled primarily by the choice of the porous membrane. The membrane emulsication technique was rst proposed by Nakashima et al. to prepare monodisperse emulsion using a particular glass membrane called Shirasu Porous Glass (SPG) membrane (SPG Technology, Miyazaki, Japan),2123 and later developed to create a variety of particulate products with novel structures and functionalities.13,15,24,25 To date, in addition to the SPG membranes, a broad range of other types of microporous membranes, such as polymeric, ceramic, metallic and microengineered devices, have been used. And several types of membrane emulsication are
Figure 1. Schematic drawing of the cross-ow membrane emulsication process.26

DOI 10.1002/jps
PREPARATION OF DRUG DELIVERY SYSTEMS BY MEMBRANE EMULSIFICATION
77
coalescence are prevented. With the assumption that the distance between the pores may be equal to the droplet diameter, the porosity e can then be calculated with the following equation: " 0:25pd2 p d2 d 2 1 0:25p x (2)
Figure 2. Schematic of a typical cross-ow membrane emulsication apparatus.17 (a) membrane module, (b) pressurizing source, (c) reservoir of dispersed phase, (d) emulsion/continuous phase storage vessel, (e) recirculation pump, (f) needle valve, and (g) pressure gauge.
porosity (5060%), and the possibility of surface modication.13,17,19 In addition to the SPG membranes, many other types of membranes include ceramic aluminum oxide (a-Al2O3),31,32 zirconium oxide,33 microporous silica glass34 and stainless steel membranes,35 and polymer membranes such as polytetrauoroethylene (PTFE)36,37 and polycarbonate38 membranes as well as polypropylene hollow bers membrane,39 have been successfully used to prepare micro/nano emulsions and particulate products. Some studies show that there is a linear relationship between the droplet size (dd) and the average micropore diameter (dp)15,26,40 dd mdp (1)
Abrahamse et al.42 calculated the maximum membrane porosity to prevent coalescence of droplets growing on neighboring micropores of 5 mm diameter to be 1.5%. However, a low porosity has the negative effect on obtaining a dispersed phase ux that makes industrial application feasible.4345 Microporous geometry has an important effect on the uniform-sized droplet obtained.46 So far, random, round, square and rectangle pores have been applied in membrane emulsication. When random-shaped/ round pore membranes are used in cross-ow membrane emulsication, a signicant external shear force is required to obtain the best control over the droplet size and size distribution.47 In cross-ow process with a tubular ceramic membrane was employed, the tube Reynolds number was required to be in the range from transient (2300 <Re < 4000) to turbulent region (Re > 4000).48 Recently, more studies towards the effects of the microporous shape were carried out with microengineered membranes.49 The membrane thickness (micropore length) plays some important roles in the control of droplet uniform and productivity.20,48 According to Darcys law, the dispersed phase ux ( fd) has the following relationship with the transmembrane pressure (DP) and the membrane thickness (L): fd K DP mL (3)
The values reported for m are from 3 to 50, depending on the ingredients and type of surfactants used, and the properties of the membrane. For SPG membranes, the range of m is between 2 and 10. For membranes other than SPG, the values of m are higher. Timgren et al.41 investigated the effects of membrane porosity/micropore spacing in the direction of the cross-ow continuous phase on the size of the droplets using computational uid dynamics (CFD). The maximum porosity can be estimated by assuming a square array of membrane micropores, while all micropores are active and steric hindrance and
DOI 10.1002/jps
where K is the membrane permeability, and m is the dispersed phase viscosity. So at a given transmembrane pressure, the membrane thickness is one of the factors to determine the dispersed phase ux. Some studies indicated that the wetting property (wall contact angle) is one of the most important characteristics affecting the droplet size/size distribution.2729,38,42,50,51 For both detachment mechanisms, the membrane should be wetted with the continuous phase and should not be wetted with the dispersed phase for proper droplet formation and droplet detachment. The wall contact angle measured in the continuous phase should be smaller than 908, that means a hydrophilic membrane for O/W emulsions is wetted with the aqueous phase and a hydrophobic membranes for W/O emulsions is wetted with the oil phase.19 The wall contact angle of the membrane depends on the dynamics of the emulsier and may be calculated with CFD.42
78
The process parameters include transmembrane pressure, cross-ow velocity/wall shear stress and temperature. The transmembrane pressure (DP) is dened as the difference between the pressure of the dispersed phase and the mean pressure of the continuous phase. In membrane emulsication, the transmembrane pressure is a critical operating parameter because it has a great inuence on the emulsication results, including the dispersed phase ux through the membrane.52 According to Eq. (3), the dispersed phase ux ( fd) increases as the transmembrane pressure increases. The capillary pressure ( Pc) is the critical pressure to make the discontinuous phase ow and can be predicted from the Laplace equation, assuming that the micropores are ideal cylinders:30 Pc 4g cos u dp (4)
interface to reduce the interfacial tension and consequently to facilitate droplet formation. A great deal of research work indicates that the interfacial tension is one of the key factors to control the droplet formation during the membrane emulsication process.38,5154,56 Emulsiers/surfactants reduce the interfacial tension between oil and water phases, facilitate droplet distribution, and decrease the transmembrane pressure (see Eq. 4). The type and concentration of emulsier/surfactant greatly inuences the adsorption kinetics and thus the dynamic interfacial tension.52 The other important role of emulsier/surfactant is to stabilize the droplet against coalescence and/or aggregation, which greatly inuence the droplet size/size distribution.54,57 Premix Membrane Emulsication The conventional cross-ow membrane emulsication process is known as direct membrane emulsication (DME). There are some potential disadvantages with this technique:19,25 (i) the relatively low maximum dispersed phase ux (typically 0.010.1 m3/ (m2 h)) that leads to low productivity; (ii) it is difcult to prepare uniform emulsion droplets when the dispersed phase has high viscosity; and (iii) uniform emulsion can only be prepared using a microporous membrane with very uniform pores. Because of these restricted conditions, there have been some limitations in choosing the dispersed phase, the continuous phase, and the membrane to obtain the desired emulsication products. The DME technique is more suitable for preparing relatively diluted emulsions with disperse phase contents up to 30 vol% for its low productivity and long production time. Recently, an alternative technique of membrane emulsication based on DME has been developed, which is called premix membrane emulsication (PME). Figure 3 shows the processes of DME and PME. In the process of PME, a preliminarily emulsied coarse emulsion (rather than a single dispersed phase in DME) is passed through a microporous membrane. The coarse emulsion can be achieved by mixing the two immiscible phases (oil and aqueous phases) together using a conventional stirrer mixer.58,59 From Figure 3, we can see there are two cases in the process of PME, PME without phase inversion and PME with phase inversion. If the membrane is wetted by the dispersed phase of coarse emulsion, for example, hydrophobic membrane wetted by oil phase, and suitable surfactants are dissolved in both phases. The PME process may result in a phase inversion, that is, a coarse O/W emulsion may be inverted into a ne W/ O emulsion. Studies indicated that PME provides several advantages over DME:6064 (i) the optimal ux with regard to droplet uniformity is much higher than
DOI 10.1002/jps
where g is the O/W interfacial tension, u is the wall contact angle, and dp the is average micropore diameter. The actual transmembrane pressure required to make the discontinuous phase ow may be greater than the capillary pressure due to tortuosities in the micropores, irregular micropore openings at the membrane surface, and the signicant effects of surface wettability.29,48,53 Cross-ow velocity is a fundamental process parameter to determine membrane emulsication characteristics because wall shear stress caused by the continuous phase is a major force to drive the droplets that are departing from the membrane micropores. Studies show that the droplet size becomes smaller as the cross-ow velocity increases, but the droplet size distribution may quickly changed to be broad with further increases in the cross-ow velocity.30,38,48,50,54 The effect of the cross-ow velocity/wall shear stress on reducing droplet size is dependent on the membrane micropore size, more effective for smaller micropore size. The phase properties that inuence the cross-ow membrane emulsication process include the dispersed phase viscosity, continuous phase viscosity, and type of emulsier/surfactant. The viscosities of dispersed and continuous phase have an important effect on the membrane emulsication results.52,54,55 According to the Darcys law (Eq. 3), an increase in the dispersed phase viscosity can result in a decrease in the dispersed phase ux through a porous membrane, which leads to a larger droplet size and broader size distribution. The continuous phase viscosity inuences the diffusion of the surfactant molecules and thus reduces the rate of the oilwater interfacial tension.56 During the droplet formation process, the surfactant molecules adsorb to the newly formed oilwater
79
Figure 3. Schematic diagrams of DME and PME processes.25
1.0 m3/(m2 h); (ii) the average droplet size is smaller with the same membrane and phase compositions; (iii) the experimental set-up in PME is generally simpler than that in DME; and (iv) the PME process parameters in PME are easier to control than those in DME. The driving pressure and emulsier properties are not critical in the PME operation as in the DME process.40 However, there are some disadvantages of PME such as a higher polydispersity of emulsion droplets compared with that prepared by DME. In order to combine the advantages of the both techniques, a multi-stage PME or repeated membrane homogenization method was developed.56,65 In the novel membrane process, the coarse emulsion is repeatedly forced through the same microporous membrane a number of times to achieve ne and uniform-sized emulsion droplets.66,67 Microchannel Emulsication Microchannel emulsication is the new development in the eld of membrane emulsication with the application of micromachining technology. Some new structure of membranes (microuidic devices) with precisely designed geometry of pores and noncylindrical
microchannels were manufactured using micromachining technology.32,6871 A schematic representation of the droplet formation process in microchannel emulsication is shown in Figure 4. In the process of terrace-based microchannel emulsication, emulsion droplets are produced by forcing the dispersed phase through the microchannels. The interfacial tension (sow) is the driving force in the droplet formation process that is divided into ination and detachment processes.72,73 The dispersed phase is forced into a disk-like shape on the terrace in the membrane. This elongated shape has a higher interfacial area with at least one radius of curvature smaller than a spherical shape in the well with radius Rd, resulting in different Laplace pressures, that is DP1 on the terrace and DP2 in the well.19,68 DP1 and DP2 can be calculated as follows: 1 1 s ow (5) DP1 s ow R1 R 2 R1 DP2 2 s ow Rd (6)
From Eqs. (5) and (6), when DP1 > DP2, R1 is less than Rd/2. Droplet can spontaneously transform into
Figure 4. A Schematic representation of the droplet formation process in microchannel emulsication.68

DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 100, NO. 1, JANUARY 2011
80
a spherical shape with a more favorable thermodynamic property and detachment occurs. From the process of microchannel emulsication, we can see that the emulsion droplet size is only determined by the geometry of microchannel when sow is regarded as a constant, and no ow of the continuous phase is needed during the emulsion droplets are formed. These make the microchannel emulsication technique attractive for producing monodisperse emulsions. The main disadvantage of microchannel emulsication for practical applications is its inherent low productivity. The dispersed phase ux is less than 0.01 m3/(m2 h) for a microchannel plate of 1 cm2. Recently, some novel microchannel emulsication techniques such as larger microchannel plates,74,75 straight-through microchannels,7678 and multiple microchannel plates have been investigated to increase the production rate. To date, considerable amounts of work about the mechanisms of membrane emulsication have been done, both experimentally and computationally. In order to better control size distribution and obtain uniform droplets at higher productivity, novel membrane emulsication techniques based on the conventional methods have been developed, such as vibrating membrane emulsication,79,80 rotating membrane emulsication,47,49,8183 and stirred cell membrane emulsication.84,85 The optimized process conditions and the effects of various parameters of these new techniques need to be investigated in more detail.
emulsion is not a very suitable system for drug delivery since W/O emulsion with high viscosity is difcult to be perfused into arteries or capillaries via catheters, and O/W emulsion cannot encapsulate most anticancer drugs that are water-soluble.86 Water-in-Oil-in-Water (W/O/W) Emulsions Higashi et al.8789 prepared W/O/W emulsions by membrane emulsication as a new drug carrier for the treatment of liver cancer by arterial injection chemotherapy. The W/O/W emulsion was prepared in two steps. First, the submicron-sized W/O emulsion was prepared using a conventional rotor-stator emulsication device. The aqueous phase contained an anticancer drug (epirubicin or carboplation), and the oil phase was made up of an iodized poppy-seed oil (Lipiodol) with polyoxyethylene (40) hydrogenated caster oil being used as the hydrophobic surfactant. Second, the W/O emulsion was passed through a hydrophilic SPG membrane into a glucose solution to obtain the multiple drug emulsion. The W/O/W emulsions with droplets sizes in a range of 170 mm can be prepared by using different SPG membranes of an appropriate micropore size. The stability experiment showed that separation or breakdown of the multiple drug emulsions did not occur for at least 40 days. Clinical studies showed that the multiple drug emulsions were effective in contracting the liver cancer texture when injected directly into the liver via the hepatic artery.90 The studies also indicated that the emulsion droplet size inuenced the anti-tumor effect of the therapy: the emulsions with proper size could accumulate in the small vessels in the tumor, while very small droplets passed through the tumor and very large droplets did not reach the tumor. The results concluded that the membrane emulsication technique makes it possible to prepare emulsions for controlled drug release with the precise design of droplet size. Vladisavljevic et al.91 produced multiple W/O/W emulsions for drug delivery by extruding a coarse W/ O/W emulsion ve times under pressures of 70 150 kPa through the SPG membranes with a mean pore size of 5.4, 7.6, 10.7, 14.8, and 20.3 mm. The studies showed that the ratio of the mean droplet size to the mean pore size after ve extrusions decreased from 1.25 to 0.68 as the pore size increased from 5.4 to 20.3 mm at the wall shear stress of continuous phase in the pores of 200 Pa. And at low continuous phase viscosity, uniform droplets with the coefcient of variation values of 0.280.34 were produced at very high transmembrane uxes exceeding 200 m3/(m2 h). The encapsulation efciency of a model drug (CaNa2EDTA) determined was 8385% in the emulsion products containing 30 vol% of inner droplets and 3050 vol% of outer drops. The results conrmed a repeated SPG membrane homogenization for conDOI 10.1002/jps
PREPARATION OF DRUG DELIVERY SYSTEM USING MEMBRANE EMULSIFICATION

Membrane emulsication has shown promising applications in various elds, such as food industry, pharmaceutical industry, cosmetic industry, chemical industry, and other elds like agriculture and environment protection. Among these applications, preparation of DDSs is one of the most attractive subjects.17 The membrane emulsication technique can be directly utilized to prepare monodisperse multiple emulsions for drug delivery. Also, this technique can afford the preparation of a variety of structure of uniform-sized particulate products by means of sequential secondary processes/reactions after primary emulsication, such as solidication, crystallization, freeze-drying, evaporation, droplet swelling, gelation, polymerization, etc.13,15,24,25 Multiple Emulsions Single and multiple emulsion productions by a direct method are the most investigated systems for membrane emulsication applications. However, single
81
trolled production of multiple emulsions with high encapsulation efciency at high production rates. W/O/W multiple emulsions can also be manufactured with the microchannel emulsication technique.69 The W/O emulsions were prepared by homogenizing a mixture of water and oil phases using a conventional homogenizer, then penetrated through the microchannel device into a second aqueous phase containing a suitable emulsier for oil phase stabilization. Tetraglycerin polyricinolate at 5 wt% dissolved in medium chain triglycerides (decane or ethyl oleate) was selected as the oil phase. A high entrapment efciency (91%) was achieved under the low shear stress conditions of microchannel emulsication.
Ethanol-in-Oil-in-Water (E/O/W) Emulsions Nakajima et al.93 presented novel E/O/W multiple emulsions that were prepared with membrane emulsication. The E/O/W emulsions are suitable to encapsulate some ingredients, such as polyphenols, taxol, androstenedione, and validamycin, which have low solubility with respect to water and oil but are soluble in ethanol. The ingredient is rst dissolved in ethanol at the concentration of 2030% and then the ethanol solution is dispersed into an oil phase using a conventional homogenizer. The E/O emulsion can be further dispersed into an aqueous phase to produce E/ O/W multiple emulsions with membrane or microchannel emulsication. These kinds of multiple emulsions have a wide range of applications as emulsion delivery systems in drugs and functional food and cosmetics. Solid Lipid Microspheres and Microcapsules Solid lipid microspheres (SLMSs) and microcapsules (SLMCs) are interesting particulate carriers for controlled drug delivery. They have several advantages of lower toxicity, better biocompatibility, higher bioavailability, higher drug encapsulation, and longtime storage than emulsions and traditional colloidal carriers.9496 The drugs encapsulated in SLMSs and SLMCs are released mainly due to the gradual degradation of the solid lipid by lipase for oral administration.97 The drug release properties of SLMSs and SLMCs for oral drug delivery are closely related to their size and size distribution. So it is very important to control the size and size distribution of SLMSs and SLMCs. Solid Lipid Microspheres Sugiura et al.98 prepared SLMSs using temperaturecontrolled microchannel emulsication and subsequent solidication of the dispersed oil phase (a high melting point edible oil). In the microchannel emulsication process, triglyceride (tripalmitin) or hydrogenated sh oil with the melting point of 588C penetrated through the microchannel device into an aqueous solution of emulsier at 708C. Monodisperse O/W emulsion with a mean droplet size of 21.7 mm and a coefcient of variation value of smaller than 4.6% was obtained. Uniform SLMSs with approximately the same size as emulsion droplets were obtained by cooling and freeze-drying of the O/W emulsion. Solid Lipid Macrocapsules Kukizaki and Goto95 produced uniform-sized SLMCs by a two-step membrane emulsication technique using tubular SPG membranes with a mean pore diameter of 0.39.9 mm. Triglyceride was used as the high-melting point solid lipid material and
Solid-in-Oil-in-Water (S/O/W) Emulsions Multiple S/O/W emulsion for oral administration of insulin was produced by Toorisaka et al.92 with SPG membrane emulsication. First, surfactant-coated insulin was achieved by mixing an aqueous solution of insulin with a hexane solution containing a lipophilic surfactant (sugar ester ER-290), followed by freezedrying. Then, surfactant-coated insulin was dispersed into soybean oil using an ultrasonication method to obtain S/O emulsion. The S/O emulsion was mixed with aqueous solution containing a hydrophilic surfactant (sugar ester L-1695), sodium cholate and D-glucose to prepare a coarse S/O/W dispersion using a rotor-stator homogenizer. Finally, the preliminary emulsied S/O/W dispersion was forced through an SPG membrane with a mean pore size of 1.1 mm several times (three or more). The monodisperse insulin multiple emulsions showed hypoglycemic activity for a long period after oral administration to rats. The authors indicated that the S/O/W emulsions with transforming insulin into a lipophilic complex and uniform droplets had good potential in the treatment of diabetes. Kukizaki64 prepared a hydrophilic drug, vitamin B12 (VB12) multiple S/O/W emulsion by premix membrane emulsication. S/O dispersion was obtained by water removal of the water droplets containing 1.1 wt% VB12 in a W/O emulsion, followed by mixing with an external water phase at 608C to form a coarse S/O/W dispersion. By forcing the resultant S/O/W dispersion through a SPG membrane with a mean pore diameter of 14.8 mm under a transmembrane pressure of 25 kPa, uniformly sized S/O/W droplets were formed at a very high transmembrane ux of 11.8 m3/(m2 h). Eventually, solid lipid microcapsules for drug delivery with a narrow particle size distribution and high hydrophilic drug entrapment efciency can be achieved by subsequent solidication of the S/O/W droplets.
DOI 10.1002/jps
82
Figure 5. Flow chart of the preparation of SLMCs using two-step SPG membrane emulsication.95 The temperature was kept at (a) 343 K and (b) 293 K.
vitamin B12 as a model drug in the study. The ow chart of the preparation of SLMCs using the twostep membrane emulsication process is shown in Figure 5. W/O emulsions were prepared in the rst membrane emulsication process using a hydrophobic SPG membrane. At the second membrane emulsication step, W/O emulsion was dispersed through a hydrophilic SPG membrane into the outer aqueous phase. The temperature of the whole membrane emulsication process was kept at a higher temperature (343 K) than the melting point of the oil phase (triglyceride). W/O/W emulsions with a narrow droplet size distribution were achieved through the temperature-controlled membrane emulsication step. The
resultant W/O/W emulsions were immediately cooled to solidify the oil phase, and were then ltered. Uniformly sized SLMCs with mean size 3.132.8 mm and high encapsulation yields of vitamin B12 of 93.2 97.7% (w/w) were obtained. The stability experiment showed that no leakage of vitamin B12 from the SLMCs was observed at body temperature (310 K) over a period of 10 days when the SLMCs were redispersed into normal saline. Kukizaki64 presented a novel method for preparation of hydrophilic drug-encapsulated SLMCs with a narrow particle size distribution via S/O/W dispersion by premix membrane emulsication, which can produce SLMCs at higher production rates and reduce the amount of water contained in the SLMCs. The microcosmic structures of SLMCs prepared from W/ O/W emulsion and S/O/W dispersion are shown in Figure 6. As shown in Figure 6a, SLMCs prepared from W/O/ W emulsion contain small aqueous droplets within larger solid lipid particles and hydrophilic drugs are dissolved in the aqueous droplets. Figure 6a illustrates that SLMCs prepared from S/O/W dispersion have a matrix type structure with nano-order particles of hydrophilic drugs embedded in the capsule. The properties of the S/O/W dispersion and hence SLMCs were affected by the homogenization process of S/O/W dispersions by premix membrane emulsication. The particle size of SLMCs and the transmembrane ux of the S/O/W dispersion were controlled by adjusting the membrane pore size and transmembrane pressure. The author concluded that micro-encapsulation of hydrophilic drugs into solid lipids by this novel method may have great potential as drug carriers. Polymer Microspheres and Microcapsules Biodegradable polymer microspheres and microcapsules with uniform size have good potential as carriers in drug delivery because of better reproducibility, more repeatable controlled release behavior,
Figure 6. Schematic illustrations of the drug-encapsulated SLMCs prepared from (a) W/O/W emulsion and (b) S/O/W dispersion.64
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 100, NO. 1, JANUARY 2011 DOI 10.1002/jps
83
higher bioavailability, targeted delivery, and functionality.99101 In recent years, uniform-sized polymer microspheres and microcapsules for drug delivery with different characteristics, hydrophilic and hydrophobic, smooth and rough, solid and hollow, porous and uniform, and with different surface charge, morphologies and diameters raging from 1 to 100 mm, were successfully produced by combining the membrane emulsication technique and subsequent polymerization process. Membrane EmulsicationDirect Polymerization In this method, the dispersed phase containing monomer, solvent, crosslinker and initiator, as well as water-insoluble oligomer, were permeated through membrane micropores into the aqueous solution of emulsier and stabilizing agent to form uniform monomer emulsion droplets (O/W or W/O/W emulsion). The suspension polymerization is then carried out by transferring the emulsion into a reactor and heating it to above the decomposition temperature of the initiator under mild agitation and nitrogen atmosphere. The initial narrow size distribution of monomer emulsion droplets can be retained throughout the polymerization process. The studies showed that the uniform-sized chitosan microspheres have potential applications in oral and other mucosal administration of protein and peptide drug because they show repeatable release behavior and excellent mucoadhesive and permeation enhancing effect across the biological surfaces.101103 The chitosan microspheres were prepared by the membrane emulsication-direct polymerization technique. Chitosan was dissolved in 1.0 wt% aqueous acetic acid containing 0.9 wt% sodium chloride, which was used as an aqueous phase. A mixture of liquid parafn and petroleum ether 7:5 (v/v) containing emulsier was used as an oil phase.101 The aqueous phase was permeated through the uniform pores of a SPG membrane into the oil phase by the pressure of nitrogen gas to form W/O emulsion. Uniform chitosan microspheres were achieved by direct polymerization of the chitosan droplets with glutaraldehyde saturated toluene as the crosslinking agent. Wei et al.104,105 prepared monodisperse chitosan microspheres with different structural and auto-uorescent properties for biological tracing and protein drug delivery by SPG membrane emulsication combined with different polymerization systems. Four different types of uniform chitosan microspheres were prepared using different crosslinkers and monomers derived from chitosan. In addition to uniformity, the SPG membrane technique also enables the preparation of chitosan microspheres with a specic particle size by the appropriate choice of the membrane micropore size. The tunability of chitosan microDOI 10.1002/jps
sphere structural properties such as surface charge, cavity size, and wall porosity enables the modication of these systems to cater to specic requirements for use as protein drug carriers.105 Monodisperse poly(glycidyl methacrylate-divinylbenzene) (P(GMA-DVB)) and poly(glycidyl methacrylateethyleneglycol dimethacrylate) (P(GMA-EGDMA)) porous microspheres were also prepared by the membrane emulsication-direct polymerization technique.106 This kind of PGMA microspheres covered with many reactive epoxy groups is easily derived to multifunctional materials and has good potential in the protein separation and enzyme immobilization. Nagashima et al.107,108 produced poly(acrylamideco-acrylic acid) hydrogel microspheres by direct polymerization of monomer droplets in a W/O emulsion after membrane emulsication. An aqueous mixture of monomers was dispersed into the oil phase to form monodisperse W/O emulsion using a hydrophobic SPG membrane treated with octadecyltrichlorosilane and trimethylchlorosilane. Uniformsized hydrogel microspheres were obtained by the polymerization of W/O emulsion at 708C. The hydrogel microspheres suitable for use in swelling-controlled drug delivery systems can absorb water or other body uids and swell when placed in the body. The swelling increases the aqueous content within the formulation as well as the polymer mesh size, enabling the drug to diffuse through the swollen network into the external biological environment. Membrane EmulsicationSolvent Evaporation The solvent evaporation method is one of the most general and simple preparation techniques of polymer microspheres for drug delivery.109 However, polydisperse emulsion droplets are obtained and polymer microspheres with a relatively wide size distribution are prepared due to the fusion or coagulation of emulsion droplets under mechanical stirring of emulsion droplets. Recently, the membrane emulsication technique has been combined with the solvent evaporation method for the preparation of polymer microspheres.110114 After the uniform droplets were prepared with membrane emulsication, the volatile solvents such as dichloromethane, chloroform, acetonitrile, toluene, etc. were evaporated, and the polymer solidied to form microspheres containing the drug in its matrix. Ma et al.110 prepared uniform biodegradable poly (lactide) microspheres, using a mixture composed of poly(lactide) (PLA) polymer, dichloromethane solvent, and lauryl alcohol cosurfactant as the oil phase and an aqueous phase containing a dispersion stabilizer poly(vinyl alcohol) (PVA) as a continuous phase. After SPG membrane emulsication, dichloromethane was evaporated at room temperature for 24 h to obtain PLA microspheres.
84
Ito et al.112114 prepared monodisperse rifampicinloaded poly(lactide-co-glycolide) (RFP-PLGA) microspheres by the membrane emulsication-solvent evaporation method. RFP-PLGA microspheres with different sizes were prepared by changing the micropore sizes of the SPG membranes and the drug release kinetics were measured in pH 7.4 PBS at 378C. Effect of polyethylene glycol (PEG) added to PVA solution (continuous phase) as a stabilizer upon the monodispersity of microspheres was studied.113 SEM photographs of RFP-PLGA microspheres modied with PEG20000 are shown in Figure 7. The results indicated that RFP-PLGA microspheres modied with PEG20000 were apparently more uniform than those prepared without PEG. The yield of RFP-PLGA microspheres was 100%. The initial burst observed in the release of RFP from RFPPLGA microspheres was suppressed by the addition of PEG. The effects of the types and the ratios of various organic solvents to dissolve PLGA were also studied.114 The authors reported that the particle size and drug loading efciency of drug-loaded PLGA microspheres dependent on the types of solvents used due to the interfacial tension between the organic solvent and aqueous phase. The organic solvents with high interfacial tension used for the preparation of PLGA microspheres were found to be suitable in terms of improvement on the properties of drug delivery formulations. Membrane EmulsicationMultiple Emulsion-Solvent Evaporation The membrane emulsication-solvent evaporation method is suitable for preparation of hydrophobic
drugs loaded polymer microspheres due to hydrophobic drugs are easily dissolved together with polymeric material in the organic solvent. However, hydrophilic drugs would be poorly encapsulated with this method. So the membrane emulsication-multiple emulsion-solvent evaporation method was developed. In this method, a hydrophilic drug is dissolved in an aqueous phase and dispersed in polymer and organic solvent to form W/O emulsions. The W/O emulsions is then dispersed again into a second aqueous phase to obtain W/O/W multiple emulsions. With this method, both hydrophobic and hydrophilic drugs can be successfully encapsulated.100,115 Uniform-sized biodegradable PLA microcapsules with lysozyme and PLA/PLGA microcapsules containing recombinant human insulin (rhI) were successfully prepared by combining the SPG membrane emulsication technique and the multiple emulsion-solvent evaporation method.100,116 For preparing lysozyme-loaded PLA microcapsules, an aqueous phase containing lysozyme was used as the internal aqueous phase, and PLA and Arlacel 83 were dissolved in a mixture solvent of dichloromethane and toluene which was used as the oil phase.100 These two solutions were emulsied by a homogenizer to form a W/O primary emulsion. The W/O emulsion was pushed through the uniform micropores (5.25 mm) of SPG membrane into the external water phase by the pressure of nitrogen gas to form the uniform W/O/W droplets. The lysozyme loaded PLA microcapsules were obtained by simply evaporating the solvent. For preparing rhI-loaded PLA/PLGA microcapsules, an aqueous phase containing rhI was used as the inner aqueous phase, and PLA/PLGA and Arlacel 83 were dissolved in a mixture solvent of dichloromethane and
Figure 7. SEM photographs of RFP-PLGA microspheres modied with PEG20000.113 Membranes with a pore size of (a) 1.00 mm, (b) 1.50 mm, (c) 1.95 mm, (d) 2.60 mm, and (e) 3.63 mm were used.
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 100, NO. 1, JANUARY 2011 DOI 10.1002/jps
85
toluene, which was used as the oil phase.116 The two solutions were emulsied by a homogenizer to form a W/O primary emulsion, and then the emulsion was forced through a SPG membrane into an outer aqueous phase to form the uniform W/O/W droplets. The drug-loaded microcapsules were then achieved by evaporating solvent from droplets. Ito et al.117119 synthesized monodisperse PLGA microspheres containing the hydrophilic model drug, blue dextran (BLD), by the solvent evaporation method and the SPG membrane emulsication technique. In order to prepare PLGA microspheres with a higher drug loading efciency, the tests of stability and productivity of the primary W/O emulsion were preliminarily examined by changing species or concentration of the oil-soluble surfactant and the ratio of water and organic solvent. BLDPLGA microspheres with various sizes between 2.0 and 10.0 mm were prepared by variation of average micropore diameters of the SPG membranes. The study indicated that the yield, monodispersity, drug loading efciency, and drug release rate of the BLDPLGA microspheres prepared by addition of PEG as codispersant into the outer aqueous phase were better than those of microspheres prepared without an additive. For subcutaneous drug delivery, biocompatible microparticles with diameters in a range of 20 100 mm are required. These are of sufcient size to contain a reasonable amounts of active ingredients, but not too big as to cause discomfort in administration. Gasparini et al.115 reported a novel membrane emulsication apparatus, a stirred dispersion cell and micropore array membrane, combined with the multiple emulsion-solvent evaporation method, to prepare uniformly sized PLGA microspheres for subcutaneous controlled drug release. In the dispersion cell, the discontinuous phase is injected at the base of the cell, where it passes through the membrane, and the droplets emerge into the continuous phase. The continuous phase is agitated by a simple two-bladed paddle controlled by a DC motor. The membrane is a thin at metal disc with monosized circular pores distributed in a highly regular array and is chemically treated in order to make the surface hydrophilic. The dispersion cell provides the ability to control the droplet size and size distribution by changing operating conditions and the chemical properties of the phases.120,121 The authors think that the membrane type used in this study is ideal for the production of water-soluble drug loaded PLGA microspheres for subcutaneous drug delivery as it is possible to produce microparticles in the size range required and with encapsulation efciencies as high as 100%. Polymer microcapsules containing inorganic substances have good potential applications in targeted
DOI 10.1002/jps
drug delivery by an external magnetic eld and bioseparation. Uniformly sized polymer microcapsules containing inorganic magnetite can be prepared by combining the SPG membrane emulsication and evaporation method in the multiple emulsions. Omi et al.122 encapsulated Fe3O4 magnetite in poly(styrene-co-acrylic acid) (PS-AA) copolymers. A solution of PS-AA copolymers in toluene was used as the oil phase, and the 2025 wt% magnetic uid was dispersed in the oil phase. An aqueous phase containing dissolved PVA and sodium lauryl sulfate (SLS) was used as a continuous phase. After membrane emulsication, toluene solvent was evaporated under reduced pressure at 50608C, and PS-AA microcapsules entrapping 3040 wt% Fe3O4 were obtained. Membrane EmulsicationDroplet Swelling For hydrophilic monomers (such as acrylate monomer), it is different to obtain polymer macrospheres with a narrow droplet size distribution using the membrane emulsication-direct polymerization technique due to the strong hydrophilic property of the SPG membrane surface. So SPG membrane emulsication was combined with the droplet swelling method to produce uniform polymer macrospheres from hydrophilic monomers. Figure 8 illustrates a schematic diagram of the droplet swelling method for the manufacture of uniform polymer microspheres. The seed emulsion containing uniform droplets was prepared by SPG membrane emulsication while the secondary small emulsion composed of hydrophilic monomers was obtained by conventional homogenization. Then, the two emulsions were mixed. The
Figure 8. Schematic method.15
diagram
of
droplet
swelling
86
adsorption of the hydrophilic monomers from the secondary emulsion on the seed emulsion droplets occurred due to the degradative diffusion mechanism.25 The uniform size of the seed droplets led to the uniformity of adsorbing the hydrophilic monomers, resulting in monodispersity of the swollen droplets even though their volume was increased by many times due to swelling. Uniform-sized polymer macrospheres were obtained after a subsequent polymerization process. The hydrophilic poly(styrene-co-divinylbenzene),123 polystyrenepolyimide,124 poly(methylmethacrylate),125 composite poly(styrene-co-methylmethacrylate) with a high content of 2-hydroxyethyl methacrylate,126 poly (styrene-co-N-dimethylaminoethyl methacrylate),127 poly (styrene-co-PEGMMA) and PEGPMMA monodisperse microspheres,128 and poly(methylmethacrylate-co-2-hydroxyethyl methacrylate) monodisperse hollow microspheres129 were produced with the membrane emulsication-droplet swelling technique. Membrane Emulsication Combined With Other Methods Chu et al.130 prepared monodisperse environmental stimulus-responsive controlled-release core-shell microcapsules using SPG membrane emulsication combined with interfacial polymerization from O/W emulsions. The dispersion phase, organic solvent containing a certain amount of monomer (terephthaloyl dichloride, TDC), was stored in a pressure-tight vessel and allowed to pass through the SPG membrane into the continuous phase under a certain pressure. The continuous phase, an aqueous solution containing an emulsier and a stabilizer, was forced to pass through the SPG membrane surface by magnetic stirring. After emulsication, another monomer (ethylene diamine, EDA), was added to the O/W emulsion dispersion in a stirred reactor, to start the interfacial polycondensation reaction between the two monomers at the O/W interface. The core-shell microcapsules with porous membranes and lineargrafted functional polymeric chains in the pores, acting as stimulus-responsive gates, were obtained after isolation by gravity precipitation and washing with deionized water. Monodisperse poly(N-isopropylacrylamide) (PNIPAM) microspheres and hollow microcapsules were produced by employing monomer-containing W/O emulsion droplets obtained from membrane emulsication as the polymerization templates and subsequent UV-induced free radical polymerization.131 When aqueous-soluble initiator ammonium persulfate (APS) was added in the dispersed aqueous phase, monodisperse PNIPAM microspheres were obtained after UV irradiation polymerization. On the other hand, monodisperse hollow PNIPAM microcapsules
were synthesized while the oil-soluble initiator 2,2dimethoxy-2-phenylacetophenone (BDK) was introduced into the continuous oil phase. The authors indicated that the PNIPAM microspheres and hollow PNIPAM microcapsules with good monodispersity presented good potential applications for temperature stimuli-responsive controlled drug release. Uniform-sized pH-sensitive quaternized chitosan microspheres were prepared by combining the SPG membrane emulsication technique and a novel thermal-gelation method.132 The mixture of quaternized chitosan solution and glycerophosphate was used as aqueous phase and dispersed in an oil phase to form uniform W/O emulsion with membrane emulsication. The droplets solidied into microspheres at 378C by the thermal-gelation method. The microspheres obtained had porous structure and showed apparent pH-sensitivity. Bovine serum albumin (BSA) as a model drug was encapsulated in the microspheres, and it was released rapidly in an acid solution and slowly in a neutral medium. The novel quaternized chitosan microspheres with pH-sensitivity can be utilized as a drug carrier (such as tumor-targeted drug carrier) targeted to organs with different pH values. From the discussion presented above, premix membrane emulsication would be a promising technique due to its high transmembrane ux and easily controllable process parameters. More recently, premix membrane emulsication combined with other techniques, such as emulsion-solvent extraction and nonsolvent-freeze drying methods, was developed. Uniform-sized amphiphilic poly(ethylene glycol-colactide) (PELA) microspheres with high encapsulation efciency of antigen were prepared with a novel method combining emulsion-solvent extraction and premix membrane emulsication.61 In this method, the preparation of coarse double emulsions was followed by additional premix membrane emulsication with proper pressure, and protein-loaded microspheres were obtained by further solidication. Also, narrowly-dispersed polylactide hollow microcapsules, with sizes 0.355.0 mm that can be used as ultrasound contrast agents, were successfully prepared by premix membrane emulsication of a polylactide/ dichloromethane/dodecane solution in alcoholwater mixtures.63 Albumin microspheres have found many applications in the drug delivery and medical diagnosis in recent years. Monodisperse albumin microspheres were prepared by membrane emulsication combined with a heat-denaturing method.133,134 A monodisperse W/O emulsion was rst prepared by passing albumin solution through a hydrophobic SPG membrane into an oil phase. Then, albumin microspheres were prepared after heating the W/O emulsion. The result from the experiment showed that the shape
DOI 10.1002/jps
87
and size of the albumin microspheres strongly depended on the concentration of the albumin solution and the heat-denaturing temperature. Nanoparticles Over the recent years, nanoparticles (nanospheres and nanocapsules) have provided huge advantages regarding drug delivery and release and emerged with their additional potential to combine diagnosis and therapy as one of the major tools in nanomedicine.135,136 Many studies have shown that nanoparticles with small size and narrow size distribution are of great importance in pharmaceutical applications.137139 Presently, the membrane emulsication technique with a moderate condition has been applied successfully to prepare nanoparticles for drug delivery and controlled release. Solid lipid nanoparticles (SLNs) composed of physiological solid lipids represent a second generation of colloidal drug carriers due to the advantages of controlled release, long-term stability, well biocompatibility and prevention of loaded drugs from degradation, and they have been investigated for various pharmaceutical applications, for example, parenteral, peroral, dermal, ocular, and pulmonary administration.140146 Charcosset et al.147150 investigated a cross-ow membrane emulsication process for the preparation of SLNs using a membrane contactor. A schematic drawing of the process is shown in Figure 9. In this process, the aqueous phase is stirred continuously and circulates tangentially to the membrane surface. The lipid phase is pressed, at a temperature above the melting point of the lipid, through the membrane micropores, allowing the formation of nanosized lipid droplets. The lipid droplets are then detached from the membrane surface by the aqueous phase owing tangentially inside the membrane module. Finally, SLNs are obtained by the cooling of the nano-sized lipid droplets to room temperature. When Kerasep ceramic membranes with micropore size of 0.1, 0.2, and 0.45 mm were used, the membrane
contactor allowed the preparation of SLNs with a lipid phase ux between 0.15 and 0.35 m3/(m2 h)), and a mean size between 70 and 215 nm.147 While hydrophilic SPG membranes with the micropore sizes of 0.2 and 0.4 mm, and hydrophobic SPG membranes with 0.4 and 1.0 mm were used, the membrane emulsication process produced SLNs with a mean size between 50 and 750 nm, and a lipid phase ux between 0.008 and 0.84 m3/(m2 h)).150 The high dispersed phase uxes obtained with the SPG membranes suggest that the scale-up could be possible for industrial applications. Zhang et al.151 presented a novel method for generating SLNs in a microchannel system with a cross-shaped junction formed by a main microchannel and two branches. The SLN formation process that occurs in the microchannel is depicted schematically in Figure 10. As shown in Figure 10, a lipid solution by dissolving the lipid in a water-miscible organic solvent is passed through the main channel while an aqueous surfactant solution is introduced into the branches simultaneously. These two liquids meet together at the cross-shaped junction and pass along the main channel. The solvent diffuses from the lipid solution stream into the aqueous phase, which results in the local supersaturation of lipid and thus leads to the formation of SLNs. The mean size, size distribution, and morphology of SLNs prepared with the microchannel system have been examined. Figure 11 shows the transmission electron microscopy (TEM) microphotograph of the obtained SLNs. From the TEM photograph, it can be seen that the SLNs obtained are nearly spherical in shape and the size distribution is narrow. The statistical measurement result of TEM has indicated that the particle size has distributed in the range of 70160 nm and the mean diameter has been 115 nm. Uniform-sized biodegradable PLA nanoparticles were prepared by combining emulsion-solvent removal and premix membrane emulsication.60 The standard formulation conditions were in the following: the
Figure 9. Schematic drawing of the membrane contactor for the preparation of SLNs.147
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 100, NO. 1, JANUARY 2011
88
Figure 10. Schematic drawing of SLN formation process in the microchannel system.151
micropore size of membrane was 1.4 mm, the transmembrane pressure was 1000 kPa, and the volume ratio of oil phase and external water phase was 1:5. The study indicated that high transmembrane pressure was a key factor to achieve uniform-sized PLA nanoparticles. The result of dispersed phase ux was not given in this study. However, for scaling up this process, it seems that the transmembrane pressure and dispersed phase ux should be further considered. According to the literature, the nanocapsules have some advantages over nanospheres, such as a lower polymer content and a higher loading capacity for lipophilic drugs. In addition, burst effect may be avoided due to the drug within a central cavity, and the drug may be better protected from degradation both during storage and after administration.152 Spironolactone-loaded polycaprolactone (PCL) nanocapsules were prepared by using a membrane contactor in laboratory and pilot scales.153 The membrane used was a Kerasep ceramic membrane, which had an active ZrO2 layer on an Al2O3TiO2 support and a mean macropore size of 0.1 mm. The optimized formulations in laboratory and pilot scales led to the preparation of spironolactone-loaded PCL nanocapsules with the mean sizes of 320 and 400 nm as
Figure 11. TEM image of SLNs prepared with the microchannel system.151
well as the high encapsulation efciencies of 96.21% and 90.56%, respectively, and both were stable for 6 months. The researchers concluded that the pilotscale production of spironolactone-loaded nanocapsules prepared using the membrane contactor was possible in an easy and reproducible way. In the eld of medicine, nanobubbles/microbubbles are expected to be applicable to areas such as the development of ultrasound contrast agents and targeted drug delivery.57,154 Kukizaki and Goto155 prepared monodisperse nanobubbles using SPG membranes with uniform micropores in a system composed of dispersed gaseous and continuous aqueous phases containing a surfactant as stabilizer. The effects of the surfactant type on the monodispersity of nanobubbles formed, bubble/pore diameter ratio, and gaseous-phase ux were examined. The study showed that monodisperse nanobubbles with a mean diameter of 360720 nm were stably produced from membranes with mean pore size of 4385 nm. The mean diameter of nanobubbles was shown to be 8.6 times larger than the mean pore size of the membrane. Therefore, the nanobubbles diameter could be controlled by the membrane pore size. More basic investigations are needed on the membrane emulsication technique used in preparing nanoparticles for drug delivery. One such investigation is the use and preparation of nanoporous membranes with uniform-sized pores. They may be prepared by the self-assembly of block copolymers, resulting in a highly-ordered nanoporous structure.156,157 But the self-assembly technique typically requires either an inorganic support or a minimum thickness to obtain sufcient mechanical strength. However, a new approach by combining the selfassembly technique with the phase inversion method may give asymmetric membranes with uniformly nanoporous structures.158 The membrane prepared by involving the phase inversion can give a high porosity, very thin top layer and excellent mechanical strength. In the preparation of nanoporous membranes, the effects of the molecular weights of the copolymer blocks and the ratios of these blocks on
DOI 10.1002/jps
89
self-assembled structures should be investigated thoroughly. Several parameters involved in the phase inversion process should also be investigated, for example, solvent, nonsolvent, additive, evaporation time, and casting solution composition.
CONCLUSIONS
All the studies carried out so far have shown that membrane emulsication offers great potential in manufacturing uniform-sized multiple emulsions and micro/nano particulate products for drug delivery. Multiple emulsions (W/O/W, S/O/W, E/O/W), solid lipid microspheres/microcapsules, biodegradable polymer microspheres/microcapsules, and nanoparticles with various average diameters and narrow size-distribution have been successfully prepared by employing different pore sizes and types of membranes, and combining membrane emulsication with sequential secondary processes/reactions, such as solidication, evaporation, droplet swelling, crystallization, gelation, and polymerization, etc. In comparison with conventional emulsication methods, the membrane emulsication technique not only has superior sizecontrollability for drug delivery systems, but also offers other advantageous: (1) higher drug encapsulation efciency, (2) excellent reproducibility, (3) mild emulsication for preserving the bioactivities of protein and peptide drugs, (4) low energy consumption, and (5) easy scale-up. From the discussion presented in this review, premix membrane emulsication would be a promising technique due to its high transmembrane ux and easily controllable process parameters. Therefore, we can anticipate that the utilization of the membrane emulsication technique in manufacturing emulsion/particulate products for drug delivery will further expand in the near future in conjunction with more basic investigations on this technique.
ACKNOWLEDGMENTS
The work was supported nancially by National Basic Research Program of China (No.2007CB935800) and Key Technology R&D Program of Hubei Province of China (No.2006AA304A07). We wish to thank Dr. Fawn Liu of Chemical Abstracts Service and Dr. Michael Vilt of the William G. Lowrie Department of Chemical and Biomolecular Engineering at The Ohio State University for their helpful discussion.
REFERENCES
1. Allen TM, Cullis PR. 2004. Drug delivery systems: Entering the mainstream. Science 303:18181822.
DOI 10.1002/jps
2. Kaparissides C, Alexandridou S, Kotti K, Chaitidou S. 2006. Recent advances in novel drug delivery systems. J Nanotech 2:111. 3. Brannon-Peppas L, Blanchette JO. 2004. Nanoparticle and targeted systems for cancer therapy. Adv Drug Del Rev 56:16491659. 4. Couvreur P, Puisieux F. 1993. Nano- and microparticles for the delivery of polypeptides and proteins. Adv Drug Del Rev 10:141162. 5. Ghosh PK, Murthy RS. 2006. Microemulsions: A potential drug delivery system. Curr Drug Del 3:167180. 6. Tseng YC, Mozumdar S, Huang L. 2009. Lipid-based systemic delivery of siRNA. Adv Drug Del Rev 61:721731. 7. Peek LJ, Middaugh CR, Berkland C. 2008. Nanotechnology in vaccine delivery. Adv Drug Del Rev 60:915928. 8. Kreuter J. 2001. Nanoparticulate systems for brain delivery of drugs. Adv Drug Del Rev 47:6581. 9. Win KY, Feng SS. 2005. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26:2713 2722. 10. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. 1994. Biodegradable long-circulating polymeric nanospheres. Science 263:16001602. 11. Gaumet M, Vargas A, Gurny R, Delie F. 2008. Nanoparticles for drug delivery: The need for precision in reporting particle size parameters. Eur J Pharm Biopharm 69:19. 12. Lince F, Marchisio DL, Barresi AA. 2008. Strategies to control the particle size distribution of poly-e-caprolactone nanoparticles for pharmaceutical applications. J Colloid Interf Sci 322:505515. 13. Charcosset C, Limayem I, Fessi H. 2004. The membrane emulsication processA review. J Chem Tech Biotech 79:209218. 14. Ito F, Fujimori H, Honnami H, Kawakami H, Kanamura K, Makino K. 2009. Study of types and mixture ratio of organic solvent used to dissolve polymers for preparation of drug-containing PLGA microspheres. Eur Polym J 45:658667. 15. Ma GH. 2003. Control of polymer particle size using porous glass membrane emulsication. China Particuol 1:105114. 16. Liu R, Huang SS, Wan YH, Ma GH, Su ZG. 2006. Preparation of insulin-loaded PLA/PLGA microcapsules by a novel membrane emulsication method and its release in vitro. 2006. Colloids Surf B: Biointerf 51:3038. 17. Nakashima T, Shimizu M, Kukizaki M. 2000. Particle control of emulsion by membrane emulsication and its applications. Adv Drug Del Rev 45:4756. 18. Joscelyne SM, Tragardh G. 2000. Membrane emulsication A literature review. J Membr Sci 169:107117. 19. Van der Graaf S, Schroen CGPH, Boom RM. 2005. Preparation of double emulsions by membrane emulsicationA review. J Membr Sci 251:715. 20. Peng SJ, Williams RA. 1998. Controlled production of emulsions using a crossow membrane: Part I: Droplet formation from a single pore. Trans Inst Chem Eng 76:894901. 21. Nakashima T, Shimizu M, Kukizaki M. 1991. Membrane emulsication by microporous glass. Key Eng Mater 61/ 62:513516. 22. Kandori K, Kishi K, Ishikawa T. 1991. Preparation of monodispersed W/O emulsions by Shirasu-porous-glass lter emulsication technique. Colloids Surf 55:7378. 23. Kandori K, Kishi K, Ishikawa T. 1991. Formation mechanisms of monodispersed W/O emulsions by SPG lter emulsication method. Colloids Surf 61:269279. 24. Gijsbertsen-Abrahamse AJ, van der Padt A, Boom RM. 2004. Status of cross-ow membrane emulsication and outlook for industrial application. J Membr Sci 230:149159.
90
25. Vladisavljevic GT, Williams RA. 2005. Recent developments in manufacturing emulsions and particulate products using membranes. Adv Colloid Interf Sci 113:120. 26. Yuan QC, Williams RA, Biggs S. 2009. Surfactant selection for accurate size control of microcapsules using membrane emulsication. Coll Surf A: Physicochem Eng Aspects 347:97103. 27. Abrahamse AJ, van Lierop R, van der Sman RGM, van der Padt A, Boom RM. 2002. Analysis of droplet formation and interactions during cross-ow membrane emulsication. J Membr Sci 204:125137. 28. Yasuno M, Nakajima M, Iwamoto S, Maruyama T, Sugiura S, Kobayashi I, Shono A, Satoh K. 2002. Visualization and characterization of SPG membrane emulsication. J Membr Sci 210:2937. 29. Luca GD, Maio FPD, Renzo AD, Drioli E. 2008. Droplet detachment in cross-ow membrane emulsication: Comparison among torque- and force-based models. Chem Eng Proce 47:11501158. 30. Vladisavljevic GT, Schubert H. 2003. Inuence of process parameters on droplet size distribution in SPG membrane emulsication and stability of prepared emulsion droplets. J Membr Sci 225:1523. 31. Vladisavljevic GT, Schubert H. 2003. Preparation of emulsions with a narrow particle size distribution using microporous alumina membranes. J Dispers Sci Technol 24:811 819. 32. Vladisavljevic GT, Lambrich U, Nakajima M, Schubert H. 2004. Production of O/W emulsions using SPG membranes, ceramic a-aluminum oxide membranes, microuidizer and a silicon microchannel plate: A comparative study. Colloids Surf 232:199207. 33. Joscelyne SM, Tragardh G. 1999. Food emulsions using membrane emulsication: Conditions for producing small droplets. J Food Eng 39:5964. 34. Fuchigami T, Toki M, Nakanishi K. 2000. Membrane emulsication using sol-gel derived macroporous silica glass. J SolGel Sci Technol 19:337341. 35. Dowding PJ, Goodwin JW, Vincent B. 2001. Production of porous suspension polymer beads with a narrow size distribution using a cross-ow membrane and a continuous tubular reactor. Coll Surf A: Physicochem Eng Aspects 180:301309. 36. Yamazaki N, Yuyama H, Nagai M, Ma GH, Omi S. 2002. A comparison of membrane emulsication obtained using SPG (Shirasu porous glass) and PTFE [poly(tetrauoroethylene)] membranes. J Dispers Sci Technol 23:279292. 37. Yamazaki N, Naganuma K, Nagai M, Ma GH, Omi S. 2003. Preparation of W/O (water-in-oil) emulsions using a PTFE (polytetrauoroethylene) membrane-a new emulsication device. J Dispers Sci Technol 24:249257. 38. Kobayashi I, Yasuno M, Iwamoto S, Shono A, Satoh K, Nakajima M. 2002. Microscopic observation of emulsion droplet formation from a polycarbonate membrane. Coll Surf A: Physicochem Eng 207:185191. 39. Vladisavljevic GT, Tesch S, Schubert H. 2002. Preparation of water-in-oil emulsions using microporous polypropylene hollow bers: Inuence of some operating parameters on droplet size distribution. Chem Eng Process 41:231238. 40. Zhou QZ, Ma GH, Su ZG. 2009. Effect of membrane parameters on the size and uniformity in preparing agarose beads by premix membrane emulsication. J Membr Sci 326:694 700. 41. Timgren A, Tragardh G, Tragardh C. 2009. Effects of pore spacing on drop size during cross-ow membrane emulsicationA numerical study. J Membr Sci 337:232239. 42. Abrahamse AJ, van der Padt A, Boom RM, Heij WBC. 2001. Process fundamentals of membrane emulsication: Simulation with CFD. AIChE J 47:12851291.
43. Schadler V, Windhab EJ. 2006. Continuous membrane emulsication by using a membrane system with controlled pore distance. Desalination 189:130135. 44. Kosvintseva SR, Gasparinib G, Holdich RG. 2008. Membrane emulsication: Droplet size and uniformity in the absence of surface shear. J Membr Sci 313:182189. 45. Egidia E, Gasparinia G, Holdicha RG, Vladisavljevica GT, Kosvintsevb SR. 2008. Membrane emulsication using membranes of regular pore spacing: Droplet size and uniformity in the presence of surface shear. J Membr Sci 323:414420. 46. Kobayashi I, Nakajima M, Chun K, Kikuchi Y, Fujita H. 2002. Silicon array of elongated through-holes for monodisperse emulsion droplets. AIChE J 48:16391644. 47. Yuan QC, Hou RZ, Aryanti N, Williams RA, Biggs S, Lawson S. 2008. Manufacture of controlled emulsions and particulates using membrane emulsication. Desalination 224:215 220. 48. Williams RA, Peng SJ, Wheeler DA, Morley NC, Taylor D, Whalley M, Houldsworth DW. 1998. Controlled production of emulsions using a cross-ow membrane, Part II: Industrial scale manufacture. Chem Eng Res Des 76:902910. 49. Yuan QC, Aryanti N, Hou RZ, Williams RA. 2009. Performance of slotted pores in particle manufacture using rotating membrane emulsication. Particuology 7:114120. 50. Luca GD, Renzo AD, Maio FPD, Drioli E. 2006. Modeling droplet formation in cross-ow membrane emulsication. Desalination 199:177179. 51. Luca GD, Drioli E. 2006. Force balance conditions for droplet formation in cross-ow membrane emulsications. J Colloid Interf Sci 294:436448. 52. Kukizaki M. 2009. Shirasu porous glass (SPG) membrane emulsication in the absence of shear ow at the membrane surface: Inuence of surfactant type and concentration, viscosities of dispersed and continuous phases, and transmembrane pressure. J Membr Sci 327:234243. 53. Christov NC, Danov KD, Danova DK, Kralchevsky PA. 2008. The drop size in membrane emulsication determined from the balance of capillary and hydrodynamic forces. Langmuir 24:13971410. 54. Hao DX, Gong FL, Hu GH, Zhao YJ, Lian GP, Ma GH, Su ZG. 2008. Controlling factors on droplets uniformity in membrane emulsication: Experiment and modeling analysis. Ind Eng Chem Res 47:64186425. 55. Vankova N, Tcholakova S, Denkov ND, Ivanov I, Vulchev VD, Danner T. 2007. Emulsication in turbulent ow: 1. Mean and maximum drop diameters in inertial and viscous regimes. J Colloid Interf Sci 312:363380. 56. Vladisavljevic GT, Shimizu M, Nakashima T. 2006. Production of multiple emulsions for drug delivery systems by repeated SPG membrane homogenization: Inuence of mean pore size, interfacial tension and continuous phase viscosity. J Membr Sci 284:373383. 57. Kukizaki M, Baba Y. 2008. Effect of surfactant type on microbubble formation behavior using Shirasu porous glass (SPG) membranes. Coll Surf A: Physicochem Eng Aspects 326:129 137. 58. Shima M, Kobayashi Y, Fujii T, Tanaka M, Kimura Y, Adachi S, Matsuno R. 2004. Preparation of ne W/O/W emulsion through membrane ltration of coarse W/O/W emulsion and disappearance of the inclusion of outer phase solution. Food Hydrocolloid 18:6170. 59. Van der Zwan E, Schroen K, van Dijke K, Boom R. 2006. Visualization of droplet breakup in pre-mix membrane emulsication using microuidic devices. Colloid Surf A 277:223 229. 60. Wei Q, Wei W, Lai B, Wang LY, Wang YX, Su ZG, Ma GH. 2008. Uniform-sized PLA nanoparticles: Preparation by premix membrane emulsication. Int J Pharm 359:294297.
DOI 10.1002/jps
91
61. Wei Q, Wei W, Tian R, Wang LY, Su ZG, Ma GH. 2008. Preparation of uniform-sized PELA microspheres with high encapsulation efciency of antigen by premix membrane emulsication. J Colloid Interf Sci 323:267273. 62. Sawalha H, Purwanti N, Rinzema A, Schroen K, Boom R. 2008. Polylactide microspheres prepared by premix membrane emulsication: Effects of solvent removal rate. J Membr Sci 310:484 493. 63. Sawalha H, Fan YX, Schroen K, Boom R. 2008. Preparation of hollow polylactide microcapsules through premix membrane emulsication: Effects of nonsolvent properties. J Membr Sci 325:665671. 64. Kukizaki M. 2009. Preparation of solid lipid microcapsules via solid-in-oil-in-water dispersions by premix membrane emulsication. Chem Eng J 151:387396. 65. Vladisavljevic GT, Shimizu M, Nakashima T. 2004. Preparation of monodisperse multiple emulsions at high production rates by multi-stage premix membrane emulsication. J Membr Sci 244:97106. 66. Zhou QZ, Wang LY, Ma GH, Su ZG. 2008. Multi-stage premix membrane emulsication for preparation of agarose micro beads with uniform size. J Membr Sci 322:98104. 67. Surh J, Jeong YG, Vladisavljevic GT. 2008. On the preparation of lecithin-stabilized oil-in-water emulsions by multistage premix membrane emulsication. J Food Eng 89:164 170. 68. Sugiura S, Nakajima M, Tong J, Nabetani H, Seki M. 2000. Preparation of monodispersed solid lipid microspheres using a microchannel emulsication technique. J Colloid Interface Sci 227:95103. 69. Sugiura S, Nakajima M, Yamamoto K, Iwamoto S, Oda T, Satake M, Seki M. 2004. Preparation characteristics of waterin-oil-in-water multiple emulsions using microchannel emulsication. J Colloid Interf Sci 270:221227. 70. Van der Graaf S, Steegmans MLJ, van der Sman RGM, Schroen CGPH, Boom RM. 2005. Droplet formation in a Tshaped microchannel junction: A model system for membrane emulsication. Coll Surf A: Physicochem Eng Aspects 266:106116. 71. Husny J, Cooper-White J. 2006. The effect of elasticity on drop creation in T-shaped microchannels. J Non-Newtonian Fluid Mechanics 137:121136. 72. Sugiura S, Nakajima M, Iwamoto S, Seki M. 2001. Interfacial tension driven monodispersed droplet formation from microfabricated channel array. Langmuir 17:55625567. n Karin CPGH. 2008. Micro73. Van Dijke KC, Boom RM, Schroe channel emulsication: From computational uid dynamics to predictive analytical model. Langmuir 24:1010710115. 74. Kobayashi I, Mukataka S, Nakajima M. 2005. Production of monodisperse oil-in-water emulsions using a large silicon straight-through microchannel plate. Ind Eng Chem Res 44:58525856. 75. Vladisavljevic GT, Kobayashi I, Nakajima M. 2008. Generation of highly uniform droplets using asymmetric microchannels fabricated on a single crystalsilicon plate: Effect of emulsier and oil types. Powder Tech 183:3745. 76. Kobayashi I, Mukataka S, Nakajima M. 2004. Effect of slot aspect ratio on droplet formation from silicon straightthrough microchannels. J Colloid Interf Sci 279:277280. 77. Kobayashi I, Takano T, Maeda R, Wada Y, Uemura K, Nakajima M. 2008. Straight-through microchannel devices for generating monodisperse emulsion droplets several microns in size. Microuid Nanouid 4:167177. 78. Kobayashi I, Murayama Y, Kuroiwa T, Uemura K, Nakajima M. 2009. Production of monodisperse water-in-oil emulsions consisting of highly uniform droplets using asymmetric straight-through microchannel arrays. Microuid Nanouid 7:107119.
DOI 10.1002/jps
79. Zhu J, Barrow D. 2005. Analysis of droplet size during crossow membrane emulsication using stationary and vibrating micromachined silicon nitride membranes. J Membr Sci 261:136143. 80. Kelder JDH, Janssen JJM, Boom RM. 2007. Membrane emulsication with vibrating membranes: A numerical study. J Membr Sci 304:5057. 81. Aryanti N, Williams RA, Hou RZ, Vladisavljevic GT. 2006. Performance of rotating membrane emulsication for o/w production. Desalination 200:572574. 82. Vladisavljevic GT, Williams RA. 2006. Manufacture of large uniform droplets using rotating membrane emulsication. J Colloid Interf Sci 299:396402. 83. Aryanti N, Hou RZ, Williams RA. 2009. Performance of a rotating membrane emulsier for production of coarse droplets. J Membr Sci 326:918. 84. Stillwell MT, Holdich RG, Kosvintsev SR, Gasparini G, Cumming IW. 2007. Stirred cell membrane emulsication and factors inuencing dispersion drop size and Uniformity. Ind Eng Chem Res 46:965972. 85. Dragosavac MM, Sovilj MN, Kosvintsev SR, Holdich RG, Vladisavljevic GT. 2008. Controlled production of oil-in-water emulsions containing unrened pumpkin seed oil using stirred cell membrane emulsication. J Membr Sci 322:178188. 86. Hino T, Kawashima Y, Shimabayashi S. 2000. Basic study for stabilization of W/O/W emulsion and its application to transcatheter arterial embolization therapy. Adv Drug Del Rev 45:2745. 87. Higashi S, Shimizu M, Nakashima T, Iwata K, Uchiyama F, Tateno S, Tamura S, Setogushi T. 1995. Arterial-injection chemotherapy for hepatocellular carcinoma using monodispersed poppy-seed oil microdroplets containing ne aqueous vesicles of epirubicin, initial medical application of a membrane emulsication technique. Cancer 75:12451254. 88. Higashi S, Maeda Y, Kai M, Kitamura T, Tsubouchi H, Tamura S, Setoguchi T. 1996. A case of hepatocellular carcinoma effectively treated with epirubicin aqueous vesicles in monodispersed iodized poppy-seed oil microdroplets. HepatoGastroenterology 43:14271430. 89. Higashi S, Tabata N, Kondo KH, Maeda Y, Shimizu M, Nakashima T, Setoguchi T. 1999. Size of lipid microdroplets effects results of hepatic arterial chemotherapy with an anticancer agent in water-in-oil-in-water emulsion to hepatocellular carcinoma. J Pharmacol Exp Ther 289:816819. 90. Higashi S, Setoguchi T. 2000. Hepatic arterial injection chemotherapy for hepatocellular carcinoma with epirubicin aqueous solution as numerous vesicles in iodinated poppy-seed oil microdroplets: Clinical application of water-in-oil-in-water emulsion prepared using a membrane emulsication technique. Adv Drug Deliv Rev 45:5764. 91. Vladisavljevic GT, Shimizu M, Nakashim T. 2006. Production of multiple emulsions for drug delivery systems by repeated SPG membrane homogenization: Inuence of mean pore size, interfacial tension and continuous phase viscosity. J Membr Sci 284:373383. 92. Toorisaka E, Ono H, Arimori K, Kamiya N, Goto M. 2003. Hypoglycemic effect of surfactant-coated insulin solubilized in a novel solid-in-oil-in-water (S/O/W) emulsion. Int J Pharm 252:271274. 93. Nakajima M, Nabetani H, Ichikawa S, Xu QY. 2003. Functional emulsions, US Patent No. 6538019. 94. Long CX, Zhang LJ, Qian Y. 2006. Preparation and crystal modication of ibuprofenloaded solid lipid microparticles. Chin J Chem Eng 14:518525. 95. Kukizaki M, Goto M. 2007. Preparation and evaluation of uniformly sized solid lipid microcapsules using membrane emulsication. Coll Surfa A: Physicochem Eng Aspects 293: 8794.
92
96. Jaspart S, Bertholet P, Piel G, Dogne JM, Delattre L, Evrard B. 2007. Solid lipid microparticles as a sustained release system for pulmonary drug delivery. Eur J Pharm Biopharm 65:4756. 97. Long K, Zubir I, Hussin AB, Idris N, Ghazali HM, Lai OM. 2003. Effect of enzymatic transesterication with axseed oil on the high-melting glycerides of palm stearin and palm olein. J Am Oil Chem Soc 80:133137. 98. Sugiura S, Nakajima M, Tong JH, Nabetani H, Sekiy M. 2000. Preparation of monodispersed solid lipid microspheres using a microchannel emulsication technique. J Colloid Interf Sci 227:95103. 99. Couvreur P, Puisieux F. 1993. Nano- and microparticles for the delivery of polypeptides and proteins. Adv Drug Del Rev 10:141162. 100. Liu R, Ma GH, Meng FT, Su ZG. 2005. Preparation of uniformsized PLA microcapsules by combining Shirasu Porous Glass membrane emulsication technique and multiple emulsionsolvent evaporation method. J Control Rel 103:3143. 101. Wang LY, Ma GH, Su ZG. 2005. Preparation of uniform sized chitosan microspheres by membrane emulsication technique and application as a carrier of protein drug. J Control Rel 106:6275. 102. Wang LY, Gu YH, Su ZG, Ma GH. 2006. Preparation and improvement of release behavior of chitosan microspheres containing insulin. Int J Pharm 311:187195. 103. Wang LY, Gu YH, Zhou QZ, Ma GH, Wan YH, Su ZG. 2006. Preparation and characterization of uniform-sized chitosan microspheres containing insulin by membrane emulsication and a two-step solidication process. Coll Surf B: Biointerf 50:126135. 104. Wei W, Wang LY, Yuan L, Wei Q, Yang XD, Su ZG, Ma GH. 2007. Preparation and application of novel microspheres possessing autouorescent properties. Adv Funct Mater 17:3153 3158. 105. Wei W, Yuan L, Hu G, Wang LY, Wu J, Hu X, Su ZG, Ma GH. 2008. Monodisperse chitosan microspheres with interesting structures for protein drug delivery. Adv Mater 20:22922296. 106. Wang RW, Zhang Y, Ma GH, Su ZG. 2006. Preparation of uniform poly(glycidyl methacrylate) porous microspheres by membrane emulsication polymerization technology. J Appl Polym Sci 102:50185027. 107. Nagashima S, Ando S, Tsukamoto T, Ohshima H, Makino K. 1998. Preparation of monodisperse poly(acrylamide-co-acrylic acid) hydrogel microspheres by a membrane emulsication technique and their size-dependent surface properties. Coll Surf B: Biointerf 11:4756. 108. Nagashima S, Koide M, Ando S, Makino K, Tsukamoto T, Ohshima H. 1999. Surface properties of monodisperse polyacrylamide-co-acrylic acid hydrogel microspheres prepared by a membrane emulsication technique. Coll Surf A: Physiochem Eng Aspects 153:221227. 109. ODonnell PB, McGinity JW. 1997. Preparation of microspheres by the solvent evaporation technique. Adv Drug Del Rev 28:2542. 110. Ma GH, Nagai M, Omi S. 1999. Preparation of uniform poly(lactide) microspheres by employing the Shirasu Porous Glass emulsication technique. Coll Surf A: Physicochem Eng Aspects 153:383394. 111. Sawalha H, Purwanti N, Rinzema A, Schroen K, Boom R. 2008. Polylactide microspheres prepared by premix membrane emulsicationEffects of solvent removal rate. J Membr Sci 310:484493. 112. Ito F, Makino K. 2004. Preparation and properties of monodispersed rifampicin-loaded poly(lactide-co-glycolide) microspheres. Coll Surf B: Biointerf 39:1721. 113. Ito F, Fujimori H, Honnami H, Kawakami H, Kanamura K, Makino K. 2008. Effect of polyethylene glycol on preparation
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
of rifampicin-loaded PLGA microspheres with membrane emulsication technique. Coll Surf B: Biointerf 66:6570. Ito F, Fujimori H, Honnami H, Kawakami H, Kanamura K, Makino K. 2009. Study of types and mixture ratio of organic solvent used to dissolve polymers for preparation of drug-containing PLGA microspheres. Eur Polym J 45:658667. Gasparini G, Kosvintsev SR, Stiliwell MT, Holdich RG. 2008. Preparation and characterization of PLGA particles for subcutaneous controlled drug release by membrane emulsication. Coll Surf B: Biointerf 61:199207. Liu R, Huang SS, Wan YH, Ma GH, Su ZG. 2006. Preparation of insulin-loaded PLA/PLGA microcapsules by a novel membrane emulsication method and its release in vitro. Coll Surf B: Biointerf 51:3038. Ito F, Fujimori H, Makino K. 2007. Incorporation of watersoluble drugs in PLGA microspheres. Coll Surf B: Biointerf 54:173178. Ito F, Fujimori H, Makino K. 2008. Factors affecting the loading efciency of water-soluble drugs in PLGA microspheres. Coll Surf B: Biointerf 61:2529. Ito F, Honnami H, Kawakami H, Kanamura K, Makino K. 2008. Preparation and properties of PLGA microspheres containing hydrophilic drugs by the SPG (Shirasu porous glass) membrane emulsication technique. Coll Surf B: Biointerf 67:2025. Kosvintsev SR, Gasparini G, Holdich RG, Cumming IW, Stillwell MT. 2005. Liquidliquid membrane dispersion in a stirred cell with and without controlled shear. Ind Eng Chem Res 44:93239330. Stillwell MT, Holdich RG, Kosvintsev SR, Gasparini G, Cumming IW. 2007. Stirred cell membrane emulsication and factors inuencing dispersion drop size and uniformity. Ind Eng Chem Res 46:965972. Omi S, Kanetaka A, Shimamori Y, Supsakulchai A, Nagai M, Ma GH. 2001. Magnetite (Fe3O4) microcapsules prepared using a glass membrane and solvent removal. J Macroencapsul 18:749765. Omi S, Taguchi T, Nagai M, Ma GH. 1997. Synthesis of 100 mm uniform porous spheres by SPG emulsication with subsequent swelling of the droplets. J Appl Polym Sci 63:931 942. Omi S, Matsuda A, Imamura K, Nagai M, Ma GH. 1999. Synthesis of monodisperse polymeric microspheres including polyimide prepolymer by using SPG emulsication technique. Colloids Surf A 153:373381. Omi S, Katami K, Taguchi T, Kaneko K, Iso M. 1995. Synthesis of uniform PMMA microspheres employing modied SPG (Shirasu Porous Glass) emulsication technique. J Appl Polym Sci 57:10131024. Ma GH, Nagai M, Omi S. 1997. Synthesis of uniform microspheres with higher content of 2-hydroxyethyl methacrylate by employing SPG emulsication technique followed by swelling process of droplets. J Appl Polym Sci 66:13251341. Ma GH, Nagai M, Omi S. 2001. Study on preparation of monodispersed poly(styrene-co-N-dimethylaminoethyl methacrylate) composite microspheres by SPG (Shirasu Porous Glass) emulsication technique. J Appl Polym Sci 79:24082424. Yoshizawa H, Maruta M, Ikeda S, Hatate Y, Kitamura Y. 2004. Preparation and pore-size control of hydrophilic monodispersed polymer microspheres for size-exclusive separation of biomolecules by the SPG membrane emulsication technique. Colloid Polym Sci 282:965971. Ma GH, Omi S, Dimonie VL, Sudol ED, El-Aasser MS. 2002. Study of the preparation and mechanism of formation of hollow monodisperse polystyrene microspheres by SPG (Shirasu Porous Glass) emulsication technique. J Appl Polym Sci 85:15301543.
DOI 10.1002/jps
93
130. Chu LY, Xie R, Zhu JH, Chen WM, Yamaguchi T, Nakao S. 2003. Study of SPG membrane emulsication processes for the preparation of monodisperse coreshell microcapsules. J Colloid Interf Sci 265:187196. 131. Cheng CJ, Chu LY, Zhang J, Zhou MY, Xie R. 2008. Preparation of monodisperse poly(N-isopropylacrylamide) microspheres and microcapsules via Shirasu-porous-glass membrane emulsication. Desalination 234:184194. 132. Wu J, Wei W, Wang LY, Su ZG, Ma GH. 2008. Preparation of uniform-sized pH-sensitive quaternized chitosan microsphere by combining membrane emulsication technique and thermal-gelation method. Coll Surf B: Biointerfaces 63:164175. 133. El-Mahdy M, Ibrahim ES, Safwat S, El-Sayed A, Ohshima H, Makino K, Muramatsu N, Kondo T. 1998. Effects of preparation conditions on the monodispersity of albumin microspheres. J Microencapsul 15:661673. 134. Muramatsu N, Nakauchi K. 1998. A novel method to prepare monodisperse microparticles. J Microencapsul 15:715723. 135. Morrow KJ, Bawa R, Wei CM. 2007. Recent Advances in basic and clinical nanomedicine. Med Clin N Am 91:805843. 136. Zuo L, Wei WC, Morris M, Wei JC, Gorbounov M, Wei CM. 2007. New technology and clinical applications of nanomedicine. Med Clin N Am 91:845862. 137. Jin S, Ye K. 2007. Nanoparticle-mediated drug delivery and gene therapy. Biotechnol Prog 23:3241. 138. Panyam J, Labhasetwar V. 2007. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Del Rev 59:718728. 139. Nishiyama N. 2007. Nanocarriers shape up for long life. Nat Nanotechnol 2:203204. 140. Muller RH, Karsten M, Sven G. 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery- a review of the state of the art. Eur J Pharm Biopharm 50:161177. der K. 2001. Solid lipid nanoparticles: Produc141. Mehnert W, Ma tion, characterization and applications. Adv Drug Del Rev 47:165196. 142. Wissing SA, Kayser O, Muller RH. 2004. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Del Rev 56:12571272. 143. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. 2007. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Del Rev 59:454477. 144. Almelda AJ, Souto EB. 2007. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Del Rev 59:478490.
145. Wong HL, Bendayan R, Rauth AM, Li YQ, Wu XY. 2007. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Del Rev 59:491504. 146. Pardeike J, Hommoss A, Muller RH. 2009. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 366:170184. 147. Charcosset C, Harati A, Fessi H. 2005. Preparation of solid lipid nanoparticles using a membrane contactor. J Control Rel 108:112120. 148. Charcosset C, Fessi H. 2005. Preparation of nanoparticles with a membrane contactor. J Membr Sci 266:115120. 149. El-Harati AA, Charcosset C, Fessi H. 2006. Inuence of the formulation for solid lipid nanoparticles prepared with a membrane contactor. Pharm Dev Tech 11:153157. 150. Doria C, Charcosset C, Barresi AA, Fessi H. 2009. Preparation of solid lipid particles by membrane emulsication Inuence of process parameters. Coll Surf A: Physicochem Eng Aspects 338:114118. 151. Zhang SH, Yun JX, Shen SC, Chen Z, Yao KJ, Chen JZ, Chen BB. 2008. Formation of solid lipid nanoparticles in a microchannel system with across-shaped junction. Chem Eng Sci 63:56005605. 152. Couvreur P, Barratt G, Fattal E, Legrand P, Vautier C. 2002. Nanocapsules Technology: A review. Crit Rev Ther Drug 19:99134. 153. Blouza IL, Charcosset C, Sfar S, Fessi H. 2006. Preparation and characterization of spironolactone-loaded nanocapsules for paediatric use. Int J Pharm 325:124131. 154. Unger EC, Porter T, Culp W, Labell R, Matsunaga T, Zutshi R. 2004. Therapeutic applications of lipid-coated microbubbles. Adv Drug Del Rev 56:12911314. 155. Kukizaki M, Goto M. 2006. Size control of nanobubbles generated from Shirasu-porous-glass (SPG) membranes. J Membr Sci 281:386396. 156. Oslon DA, Chen L, Hillmyer M. 2008. Templating nanoporous polymers with ordered block copolymers. Chem Mater 20:869 890. 157. Hawker C, Russell TP. 2005. Block copolymer lithography: Merging bottom-up with top-down processes. MRS Bull 30:952966. 158. Peinemann KV, Abetz V, Simon PFW. 2007. Asymmetric superstructure formed in a block copolymer via phase separation. Nat Mater 6:992996.
DOI 10.1002/jps

Preparation of Drug Delivery Systems

Enviado por

Dados do documento

Descrição original:

Direitos autorais

Formatos disponíveis

Compartilhar este documento

Compartilhar ou incorporar documento

Opções de compartilhamento

Você considera este documento útil?

Este conteúdo é inapropriado?

Direitos autorais:

Formatos disponíveis

Preparation of Drug Delivery Systems

Enviado por

Direitos autorais:

Formatos disponíveis

REVIEW Preparation of Uniform-Sized Multiple Emulsions and Micro/ Nano Particulates for Drug Delivery by Membrane Emulsication

WEI LIU,1,2 XIANG-LIANG YANG,1 W.S. WINSTON HO2,3

JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 100, NO. 1, JANUARY 2011

LIU, YANG, AND WINSTON HO

PRINCIPLES OF MEMBRANE EMULSIFICATION

Figure 1. Schematic drawing of the cross-ow membrane emulsication process.26